エンジェルマン症候群の治療に向けて,長い非コーディングRNAを標的とする
Linyan Meng1, Amanda J Ward2, Seung Chun2
1Department of Molecular and Human Genetics, Baylor College of Medicine, and Texas Children's Hospital, Houston, Texas 77030, USA.
Nature
|December 4, 2014
まとめ
研究者は,UBE3A-ATSを減少させ,父親のUBE3A遺伝子を活性化するために,アンチセンセオリゴヌクレオチド (ASO) を使用してアンジェルマン症候群のための新しい遺伝子治療を開発し,この神経発達障害の潜在的な治療を提供しました.
科学分野:
- 遺伝学 遺伝学とは
- 神経科学は神経科学である.
- 分子生物学は分子生物学である.
背景:
- アンジェルマン症候群は,UBE3A遺伝子の母親の欠乏によって引き起こされる神経発達障害です.
- 無傷の父親のUBE3Aアレルは,UBE3A反意味トランスクリプト (UBE3A-ATS) によって静止されます.
- アンジェルマン症候群の現在の治療法は,遺伝子特異性がない.
研究 の 目的:
- エンジェルマン症候群の遺伝子特異的な治療介入を開発する.
- 父親のUBE3A発現を回復するためにUBE3A-ATSを減少させる可能性を調査する.
- アンジェルマン症候群の治療における反感覚オリゴヌクレオチド (ASO) の有効性を評価する.
主な方法:
- UBE3A-ATS.を標的にし,減らすために,アンチセンスオリゴヌクレオチド (ASO) を開発しました.
- アンジェルマン症候群のマウスモデルにインビトロおよびインビボでASOを投与した.
- UBE3A-ATSの減少,父親のUBE3A発現,およびUBE3Aタンパク質の回復を評価した.
- 治療されたマウスモデルで評価された認知欠陥.
主要な成果:
- ASO治療は特にUBE3A-ATSレベルを低下させた.
- 神経細胞では,父親のUbe3aアレルの持続的な非静止が観察されました.
- アンジェルマン症候群のマウスモデルでは,UBE3Aタンパク質の部分的な回復が達成されました.
- 治療されたマウスでは,いくつかの認知障害の改善が認められた.
結論:
- ASO媒介によるUBE3A-ATSの減少は,父親のUBE3A発現を活性化するための実行可能な戦略です.
- このアプローチは,エンジェルマン症候群の遺伝子特異的な治療介入の可能性を提供します.
- 現型修正と臨床有効性を確認するためにさらなる研究が必要である.
さらに関連する動画
07:02Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
14.6K
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
8.2K
関連する概念動画
02:39lncRNA - Long Non-coding RNAs
10.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
02:39lncRNA - Long Non-coding RNAs
3.9K
3.9K
02:15Experimental RNAi
8.4K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.4K
02:30siRNA - Small Interfering RNAs
19.1K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.1K
02:18Alternative RNA Splicing
27.6K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
27.6K
01:23RNA Interference
29.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
29.0K